Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide.
No relevant relationships to disclose
Employment or Leadership Position - Oncoscience
Stock Ownership - Oncoscience
Honoraria - Oncoscience
Research Funding - Oncoscience